March Madness: Boston Scientific Continues Buying Spree

Boston Scientific is set to acquire NxThera, a urology specialist, for about $406 million. The transaction consists of an upfront cash payment of $306 million, and up to an additional $100 million in potential commercial milestone payments over the next four years. The deal is set to close in the second quarter of 2018. Maple Grove, MN-based NxThera has developed and commercialized the Rezūm system, which is a minimally invasive therapy for the treatment of symptoms arising from benign prostatic hyperplasia (BPH). The system was cleared by FDA in 2015 and has CE mark. Treatment with the Rezūm system is typically performed in a physician's office without general anesthesia and uses water vapor to remove excess prostate tissue thereby alleviating obstruction to flow, which helps reduce BPH-related symptoms.      A study published in the March issue of the Journal of Urology demonstrated that over a three year period, patients treated with the Rezūm system had clinical progression rates that were five times lower than reported rates of patients treated with daily, long-term medications. Additional clinical data from a randomized controlled trial demonstrated that patients treated with the Rezūm system had a 51% reduction in their symptoms at 24 months post-treatment and maintained a 50% reduction in BPH symptoms at three years post-treatment. The BPH market is large and underpenetrated. Boston Scientific estimates BPH affects 110 million men worldwide. Pleasanton, CA-...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news